Finding the Right Balance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Finding the Right Balance

Equipment and Processing Report

Untitled Document

Q: When a pharmaceutical quality-control or quality-assurance laboratory weighs a monogrammed substance for assay, the balance used to weigh the sample must conform to the requirements laid out in US Pharmacopeia <41>. How do you assign a minimum sample weight for a USP <41> balance application when the tested repeatability gives a standard deviation (SD) of zero?

A: The idea that 0 SD for a repeatability test means an excellent result is a misconception. In fact, 0 SD indicates a problem with the choice of instrument or methodology used for the test.

If a measuring instrument indicates a 0 SD during testing, it does not have enough sensitivity to measure the tested mass accurately. Because most balances used for USP <41> applications are analytical balances (i.e., those with 0.1 or 0.01mg readability), a result of 0 SD during a repeatability test should never be considered a pass criterion for minimum-weight verification. The same can be said for micro and ultramicro balances (i.e., those with 1 or 0.1µg readability). A 0 SD generally means that the balance does not have enough displayed digits (i.e., readability) for the tested minimum weight. USP <41> recommends a limit of 0.1% error in the measurement. If the balance cannot display 0.1% of the desired minimum weight, then testing for suitability is pointless because you cannot meet the USP requirements.

Course-reading top-loader balances sometimes give a 0 SD result during minimum-weight tests. The problem is that top-loader balances of low readability (e.g., 0.1 or 0.01 g) are inherently insensitive because of their course readability. The theoretical test mass needed to achieve suitable sensitivity levels with such an instrument may be way beyond the balance’s actual capacity. In compliance with current legislation, the correct solution is to employ a balance with the correct readability to display 0.1% of the net sample under investigation.

—Ian Ciesniewski, technical director at Mettler Toledo

 

If you have a problem with your equipment or process, an industry expert may have the solution. Please send your question to Erik Greb, editor of Equipment and Processing Report, and we may be able to provide an answer in a future issue. All questions will remain anonymous.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Equipment and Processing Report,
Click here